NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

The effect of fluconazole on nevirapine pharmacokinetics.

Pitt J, Orrell CJ, Geel J, Van Dyk M, Wood R; International Conference on AIDS (15th : 2004 : Bangkok, Thailand).

Int Conf AIDS. 2004 Jul 11-16; 15: abstract no. WeOrB1239.

Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa

Objective: With the widespread use of nevirapine as first line therapy in antiretroviral access programmes, it is becoming more important to understand the interactions between this drug and other medications commonly used in the treatment of HIV positive individuals. One such interaction is that between nevirapine and fluconazole. This study assessed the effects of nevirapine on the steady-state pharmacokinetics of fluconazole and that of fluconazole on nevirapine steady state pharmacokinetics. Methods: A single-center, open-label, single-arm trial of pharmacokinetic parameters of fluconazole alone and in combination with nevirapine in 24 patients on a stable regimen of three nucleoside analogue antiretrovirals. Results: The nevirapine effect on fluconazole pharmacokinetic parameters is minimal. However, the clearance of nevirapine was halved during concomitant administration of fluconazole resulting in an approximate doubling of nevirapine Cmin, Cmax and AUC. 95% of drug-related adverse events occurred during the period of co-administration of nevirapine and fluconazole. During this phase 25% (CI 7-43%) of patients developed serious hepatotoxicity including two cases of clinical hepatitis (8.3%) and four cases of transient grade 4 transaminase elevation (16.7%). Discussion: Nevirapine did not significantly influence the plasma levels of fluconazole, however fluconazole co-administration was associated with a doubling of nevirapine levels. The incidence of serious hepatotoxicity with the combination (25.0%) was much higher than reported in other studies using nevirapine alone (2.5% at 4 weeks). Conclusion Because of the pharmacokinetic interaction and apparent increased incidence of hepatotoxicity, the combination of nevirapine and fluconazole should be used with caution. Monitoring of liver functions tests is advisable.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Drug Interactions
  • Fluconazole
  • Humans
  • Incidence
  • Liver Function Tests
  • Nevirapine
  • Single Person
  • pharmacokinetics
Other ID:
  • GWAIDS0039226
UI: 102283442

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov